CN102258528B - Application of new hesperidin - Google Patents
Application of new hesperidin Download PDFInfo
- Publication number
- CN102258528B CN102258528B CN 201010264502 CN201010264502A CN102258528B CN 102258528 B CN102258528 B CN 102258528B CN 201010264502 CN201010264502 CN 201010264502 CN 201010264502 A CN201010264502 A CN 201010264502A CN 102258528 B CN102258528 B CN 102258528B
- Authority
- CN
- China
- Prior art keywords
- neohesperidin
- skin microcirculation
- skin
- extract
- microcirculation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to new application of new hesperidin, in particular to application of the new hesperidin or plant extract containing the new hesperidin to preparation of products for improving and/or promoting skin microcirculation or eliminating and/or relieving diseases or states which are relevant to poor skin microcirculation. The invention also a composition containing effective quantity of new hesperidin or containing the plant extract of the new hesperidin and a method for improving and/or promoting the skin microcirculation or eliminating and/or relieving the diseases or the states which are relevant to the poor skin microcirculation by using the new hesperidin. The new hesperidin is beneficial to the skin microcirculation, particularly the skin microcirculation of eyes.
Description
Technical field
The present invention relates to the new purposes of neohesperidin, the new purposes aspect cosmetics particularly, more especially neohesperidin is as the effect of the chemical composition of improving skin microcirculation, particularly in the new purposes that is used for dispelling aspect the eye black eye.
Background technology
The structure of human body eye part skin is different from other position of human skin, at first on the cheekbone of circumference of eyes and bridge of the nose both sides is blood vessel and lymph " delivery site ", this position is the place that facial venule crosses, and blood vessel is very young carefully to be enriched, if the eye microcirculation is not enough, will cause poor blood circulation or tissue edema to cause blood congestive edema, moisture to hoard; Simultaneously, the skin of circumference of eyes is very thin only to be 1/10 of other position skin thickness, by very easily atropurpureus occurring near the eyes behind the light refraction, forms black eye.And fatigue, pressure, the reason such as do not have enough sleep are the key factors that causes microcirculation disturbance, and age is gradually long in addition, and skin will reduce approximately 6% thickness in per ten years, and black eye will be more obvious.Therefore no matter of short duration or long-term, the women of all ages and classes once or always had the experience that is perplexed by the black eye problem, needed be improved by the microcirculation that improves skin around the eyes.
After using, can significantly improve the approach such as a lot of natural plant extracts oral administration of bibliographical information and vein the microcirculation of skin, as: Flos Carthami extract, Radix Salviae Miltiorrhizae extract, Folium Ginkgo extract, butchers broom extract, Flos Caraganae Sinicae extract, Citrus reticulata Blanco extract, Radix Ginseng extract etc.But simultaneously also bibliographical information has been arranged from above-mentioned plant extract, extract the local topicals such as some monomer components of being purified to such as TANSHINONES, ginsenoside, β-aescine, Lu Si saponin, ginkgetin behind human body skin to microcirculatory effect, the result shows that these chemical substances all can not significantly improve skin microcirculation after being locally applied to skin surface.
The skin microcirculation of improving of selling on the market at present (is for example improved the eye part skin microcirculation, for example dispel black eye) the eye product emerge in an endless stream, to have added some plant extracts mostly, but on the one hand be which kind of or what constituents performance effect is indefinite in these extracts, these products are dispelled black-eyed effect and not obvious on the other hand, the product that great majority improve skin microcirculation (for example being used for dispelling black eye) do not bring about the desired effect after consumer uses (black eye of for example dispelling effect).Therefore seek the chemical substance that behind local topical, can significantly improve skin microcirculation, improve skin microcirculation in order to exploitation and (for example improve the eye part skin microcirculation, for example dispel black eye) product, particularly dispel black-eyed eyeware products and solution for lenses and contact lenses, be still the direction of those skilled in the art's primary study.
Neohesperidin is a kind of flavanone, derive from Rutaceae Poncirus plant trifoliate orange (latin name: fruit Poncirus trifoliata (L.) Raf.), its structural formula is as follows:
Molecular formula C
28H
34O
15, molecular weight 610.56.Be mainly used in the preparation of dihydrochalcone-type novel sweetener.According to the literature, neohesperidin has certain curative effect aspect antiallergic, and there is not yet report about neohesperidin in the purposes of improving aspect the skin microcirculation.Develop the product that new having improve the skin microcirculation effect and particularly have the product that improves the eye part skin microcirculation, be still those skilled in the art expectation.
Summary of the invention
The object of the present invention is to provide neohesperidin in the new purposes of the aspect of improving skin microcirculation (for example improve the eye part skin microcirculation, for example dispel black eye).The present invention finds unexpectedly, and the plant extract that uses neohesperidin or comprise neohesperidin can improve skin microcirculation effectively, particularly improves the eye part skin microcirculation, more especially can effectively dispel black eye.The present invention is based on above-mentioned discovery and be accomplished.
Summary of the invention:
For this reason, the plant extract that first aspect present invention provides neohesperidin or comprised neohesperidin is for the preparation of improving and/or promoting skin microcirculation, perhaps eliminate and/or the product of the bad relevant disease of alleviation and skin microcirculation or state in purposes.For example be used for to improve and/or promoting mammal (particularly people) skin microcirculation, perhaps eliminate and/or the product of the bad relevant disease of alleviation and mammal (particularly people) skin microcirculation or state in purposes.
According to the purposes of first aspect present invention, wherein said skin microcirculation is the eye part skin microcirculation.
According to the purposes of first aspect present invention, wherein saidly refer to and the bad relevant disease of eye part skin microcirculation or state with the bad relevant disease of skin microcirculation or state.
According to the purposes of first aspect present invention, wherein saidly refer to black eye with the bad relevant disease of eye part skin microcirculation or state.
According to the purposes of first aspect present invention, the wherein said plant extract that comprises neohesperidin refers to extract the extract that obtains by the fruit of Rutaceae Poncirus plant trifoliate orange (Poncirus trifoliata (L.) Raf.).
Purposes according to first aspect present invention, the wherein said plant extract that comprises neohesperidin refers to extract the extract that obtains by the fruit of Rutaceae Poncirus plant trifoliate orange (Poncirus trifoliata (L.) Raf.), and neohesperidin content is not less than 50 % by weight in this extract.In a preferred embodiment, neohesperidin content reaches that 60 % by weight are above, 70 % by weight above, 80 % by weight are above, 85 % by weight are above, 90 % by weight are above or more than 95 % by weight in this extract.
According to the purposes of first aspect present invention, wherein said product is the product of local application.
According to the purposes of first aspect present invention, wherein said product is the product of the local application of external preparation for skin.
According to the purposes of first aspect present invention, wherein said product is the product for the local application of eye part skin.
According to the purposes of first aspect present invention, wherein said product is cosmetics.
According to the purposes of first aspect present invention, wherein said product is the form that is solution, emulsus, paste, emulsifiable paste or gel.
According to the purposes of first aspect present invention, comprise in the wherein said product: (1) neohesperidin or comprise the plant extract of neohesperidin, and the acceptable excipient of (2) physiology.
According to the purposes of first aspect present invention, comprise in the wherein said product: (1) neohesperidin or comprise the plant extract of neohesperidin, and the acceptable excipient of (2) physiology; And wherein said neohesperidin or the plant extract that comprises neohesperidin account for the percent of this product gross weight and count the 0.01-20 % by weight with neohesperidin.In one embodiment.Described neohesperidin or the plant extract that comprises neohesperidin account for the percent of this product gross weight and count 0.01-15 % by weight, 0.01-10 % by weight, 0.05-15 % by weight, 0.1-10 % by weight, 0.2-10 % by weight or 0.2-5 % by weight with neohesperidin.
Second aspect present invention provides a kind of compositions, and it comprises: the neohesperidin of (1) effective dose or comprise the plant extract of neohesperidin, and the optional acceptable excipient of (2) physiology.
According to the compositions of second aspect present invention, it comprises: the neohesperidin of (1) effective dose or comprise the plant extract of neohesperidin, and the optional acceptable excipient of (2) physiology; And wherein said neohesperidin or the plant extract that comprises neohesperidin account for the percent of said composition gross weight and count the 0.01-20 % by weight with neohesperidin.In one embodiment.Described neohesperidin or the plant extract that comprises neohesperidin account for the percent of said composition gross weight and count 0.01-15 % by weight, 0.01-10 % by weight, 0.05-15 % by weight, 0.1-10 % by weight, 0.2-10 % by weight or 0.2-5 % by weight with neohesperidin.
According to the compositions of second aspect present invention, the wherein said plant extract that comprises neohesperidin refers to extract the extract that obtains by the fruit of Rutaceae Poncirus plant trifoliate orange (Poncirus trifoliata (L.) Raf.).
Compositions according to second aspect present invention, the wherein said plant extract that comprises neohesperidin refers to extract the extract that obtains by the fruit of Rutaceae Poncirus plant trifoliate orange (Poncirus trifoliata (L.) Raf.), and neohesperidin content is not less than 50 % by weight in this extract.In a preferred embodiment, neohesperidin content reaches that 60 % by weight are above, 70 % by weight above, 80 % by weight are above, 85 % by weight are above, 90 % by weight are above or more than 95 % by weight in this extract.
According to the compositions of second aspect present invention, it is as improving and/or promote skin microcirculation, perhaps eliminating and/or alleviation and the bad relevant disease of skin microcirculation or the product of state.In one embodiment, described skin microcirculation is the eye part skin microcirculation.In one embodiment, describedly refer to and the bad relevant disease of eye part skin microcirculation or state with the bad relevant disease of skin microcirculation or state.In one embodiment, wherein saidly refer to black eye with the bad relevant disease of eye part skin microcirculation or state.
According to the compositions of second aspect present invention, it is the product as local application.
According to the compositions of second aspect present invention, it is the product as the local application of external preparation for skin.
According to the compositions of second aspect present invention, it is the product as the local application of eye part skin.
According to the compositions of second aspect present invention, it is cosmetics.
According to the compositions of second aspect present invention, it is the form that is solution, emulsus, paste, emulsifiable paste or gel.
Third aspect present invention is provided at improves and/or promotes skin microcirculation in the individuality that needs, perhaps eliminate and/or alleviation and the bad relevant disease of skin microcirculation or the method for state, the method comprises to this individuality to be used the neohesperidin of effective dose or comprises the plant extract of neohesperidin.
According to the method for third aspect present invention, wherein said skin microcirculation is the eye part skin microcirculation.
According to the method for third aspect present invention, wherein saidly refer to and the bad relevant disease of eye part skin microcirculation or state with the bad relevant disease of skin microcirculation or state.
According to the method for third aspect present invention, wherein saidly refer to black eye with the bad relevant disease of eye part skin microcirculation or state.
According to the method for third aspect present invention, the wherein said plant extract that comprises neohesperidin refers to extract the extract that obtains by the fruit of Rutaceae Poncirus plant trifoliate orange (Poncirus trifoliata (L.) Raf.).
Method according to third aspect present invention, the wherein said plant extract that comprises neohesperidin refers to extract the extract that obtains by the fruit of Rutaceae Poncirus plant trifoliate orange (Poncirus trifoliata (L.) Raf.), and neohesperidin content is not less than 50 % by weight in this extract.In a preferred embodiment, neohesperidin content reaches that 60 % by weight are above, 70 % by weight above, 80 % by weight are above, 85 % by weight are above, 90 % by weight are above or more than 95 % by weight in this extract.
According to the method for third aspect present invention, the neohesperidin of wherein said effective dose or the plant extract that comprises neohesperidin are to use with the form of the product of local application.
According to the method for third aspect present invention, the neohesperidin of wherein said effective dose or the plant extract that comprises neohesperidin are to use with the form of the product of the local application of external preparation for skin.
According to the method for third aspect present invention, the neohesperidin of wherein said effective dose or the plant extract that comprises neohesperidin are to use with the form of the product of the local application that is used for eye part skin.
According to the method for third aspect present invention, the neohesperidin of wherein said effective dose or the plant extract that comprises neohesperidin are to use with the form of cosmetics.
According to the method for third aspect present invention, the neohesperidin of wherein said effective dose or the plant extract that comprises neohesperidin are that the form that is solution, emulsus, paste, emulsifiable paste or gel is used.
The feature that arbitrary specific embodiments of either side of the present invention or this either side has is equally applicable to other arbitrary specific embodiments of this aspect, is applicable to too arbitrary specific embodiments of other either side or other either side.
Detailed Description Of The Invention:
The below is further described with characteristics to various aspects of the present invention.
All documents that the present invention quotes from, their full content is incorporated this paper by reference into, and if the expressed implication of these documents and the present invention when inconsistent, be as the criterion with statement of the present invention.In addition, various terms and phrase that the present invention uses have the general sense of well known to a person skilled in the art, nonetheless, the present invention still wishes at this these terms and phrase to be described in more detail and to explain, the term of mentioning and phrase are as the criterion with the implication that the present invention was explained if any inconsistent with known implication.
As described herein, term " skin microcirculation " refers to the capillary network under the dermal layer of the skin, is that the terminal portion of circulation divides, and belongs to blood capillary, is the arteriovenous interface point, is the place that blood and histiocyte carry out mass exchange.Skin microcirculation is the dynamical system of a complexity, and skin color, thermoregulation, skin metabolism and transdermal transfer are played very important effect, direct cutaneous health.
As described herein, term " with the bad relevant disease of skin microcirculation or state ", refer to pathologic or non-pathologic condition or abnormal conditions bad owing to the local skin microcirculation or that obstacle occurs, such as dermatitis, pigmentation, skin aging, palor, red blood streak, local skin congestive edema, local moisture hoard, black eye etc.
As described herein, term " improvement ", " promotion ", " elimination " " alleviation ", for example " improvement and/or promotion skin microcirculation " described herein and " elimination and/or alleviation and the bad relevant disease of skin microcirculation or state ", be to instigate bad owing to the local skin microcirculation or obstacle pathologic or non-pathologic condition or abnormal conditions occur and brings about a wholesome effect, for example improve the local skin microcirculation, promote the local skin microcirculation, eliminate bad owing to the local skin microcirculation or pathologic or non-pathologic condition or abnormal conditions appear in obstacle, alleviate bad owing to the local skin microcirculation or pathologic or non-pathologic condition or abnormal conditions appear in obstacle.Such as improving red blood streak, eliminate pigmentation, eliminate edema, alleviate congestive edema, eliminating black eye etc.
As described herein, term " physiology is acceptable " refers to that the physiology is compatible, particularly use in the external preparation for skin product with contact skin the time operable, such as the side effect such as zest that do not produce skin.Particularly such as operable diluent, surfactant, thickening agent, emollient etc. in the cosmetics.
As described herein, term " effective dose " refers to realize treating, prevent, alleviate and/or alleviating the dosage of disease of the present invention or disease in the experimenter.
As described herein, term " compositions ", it can also refer to " cosmetics ", " cosmetic composition ", " pharmaceutical composition ", and it is used in realizes treating, prevent, alleviate and/or alleviating disease of the present invention, disease or condition in the individuality.
As described herein, term " individuality ", it can also refer to that " experimenter ", " patient " or other accept the present composition to improve and/or to promote the skin microcirculation of its appearance, perhaps eliminate and/or alleviate its appearance with the bad relevant disease of skin microcirculation or the animal of state, mammal particularly, such as people, Canis familiaris L., monkey, cattle, horse etc., particularly people.
As described herein, term " eye part skin microcirculation " refers to the microcirculation in the skin of around eyes.
According to the present invention, described neohesperidin can be extracted by the fruit of Rutaceae Poncirus plant trifoliate orange (Poncirus trifoliata (L.) Raf.) and obtain, and is also can be according to chemical method known in the art synthetic or get through biotransformation.This neohesperidin can be monomeric compound, also can be that neohesperidin content is not less than the extract of 50% (w/w).In the present invention, in neohesperidin monomeric compound use amount, neohesperidin is with 0.01%-20% (w/w), preferred 0.05%-15% (w/w), most preferably the concentration of 0.1%-10% (w/w) is used for compositions of the present invention.
The present invention also comprises the cosmetics skin care compositions that contains neohesperidin.
The present invention relates to a kind of cosmetics skin care compositions, said composition comprises: the neohesperidin that (1) exists with the amount of 0.1%-10% weight; (2) acceptable vehicle in the cosmetics.
Using neohesperidin in compositions of the present invention is to dispel the black-eyed effect of eye in order to reach.
The compositions and methods of the invention comprise that also acceptable vehicle is used as diluent, dispersant or the carrier of active component in the compositions in the cosmetics, thereby promote its distribution when compositions is used for skin.
Vehicle beyond the water comprises liquid or solid emollient, surfactant, solvent, thickening agent.
Various types of active component all can be present in the cosmetic composition of the present invention.Active substance is defined as the material of the composition of the physical property that is different from emollient and only improves compositions.
In one embodiment of the invention, provide a kind of compositions with following prescription:
According to the present invention, by the topical application neohesperidin, can reach the black-eyed effect of eye that reduces or eliminates.
The present invention relates to the new purposes, particularly neohesperidin of neohesperidin aspect cosmetics as the chemical composition of improving skin microcirculation in the new purposes of dispelling aspect the eye black eye.Preferably in this purposes, described neohesperidin exists with the amount that accounts for compositions 0.01%-10% weight.
In order to utilize better neohesperidin, the present invention is studied the short microcirculation effect that neohesperidin is locally applied to skin surface, the result can obviously improve skin microcirculation after showing the neohesperidin local topical, the inventor is applied in the eyeware products and solution for lenses and contact lenses, and the discovery neohesperidin has dispels black-eyed effect significantly.
The specific embodiment
Can conduct further description the present invention by following example, yet scope of the present invention is not limited to following example.One of skill in the art can understand, and under the prerequisite that does not deviate from the spirit and scope of the present invention, can carry out various variations and modification to the present invention.
The present invention carries out generality and/or concrete description to the material and the test method that use in the test.Although for realizing that the employed many materials of the object of the invention and operational approach are well known in the art, the present invention still does detailed as far as possible description at this.In the context of the present invention, if without other special explanation, % represents wt%, i.e. percetage by weight.
Embodiment 1: observe the local topical neohesperidin to skin microcirculation with laser-Doppler
Impact
Short microcirculation test method: getting body weight is the male Japan large ear rabbit of 3.0-3.5kg, after hair is shaved at the back, delimits 10 points of test blood flow without the hair-fields rabbit with marking pen, and each 5 point of left and right sides are drawn point and avoided trunk; Before being coated with sample, measure the blood flow basic value of 10 of each group experiment rabbits with laser Doppler flowmetry, each is organized left side, rabbit back and smears blank solution, solution (three treated animals that contain neohesperidin are smeared on the right side, liquor strength is respectively 0.5% (w/v), 1% (w/v), 2% (w/v), 0.1 milliliter of every animal consumption), parallel 3 rabbits of each concentration sample.With the medicinal liquid of similar approach oral 2% (w/v), dosage is 100 times of 2% (w/v) liquid medicine painting group.Every Blood Flow Value of measuring same area through 1 hour with laser Doppler flowmetry after the medication, measure altogether 24 hours, and calculate the blood flow variability index, and estimate neohesperidin to the impact of rabbit back blood flow, the higher expression of blood flow variability index promotes that the microcirculation effect is better.Experimental result is carried out statistical analysis with SPSS11.5 software, and measurement data is used t test evaluation result of the test, and P＜0.1 can be considered to have statistical significance.In the result of table 1, listed in 24 hours test, the All Time point of P＜0.1 occurred.
Table 1 variable concentrations neohesperidin promotes the effect of rabbit skin microcirculation
Annotate: when "-" expression is with 2% administering medicine liquid in the table, in 24 hours test, the time point of P＜0.1 do not occur.
Result of the test shows, after the sample that contains the variable concentrations neohesperidin is smeared at the rabbit back, compares with blank side, can significantly improve rabbit skin blood capillary blood flow.
Embodiment 2: neohesperidin is dispelled the black-eyed effect of eye
Method: 8 weeks, two kinds of prescriptions both sides eye contrast service test is adopted in this research.
In this research, recruited 50 of middle severe black eye volunteers, guaranteed that each paired comparison group efficiently individual quantity is 15 people.Random assortment and left/right balance are used between the experimenter, and eye one side is smeared the compositions that contains neohesperidin, and opposite side is smeared the compositions that does not contain neohesperidin, continue for 8 weeks.In 0 week (process before), 2 weeks, 4 weeks, 6 all and 8 weeks it was dispelled the black eye effect and carry out the effect evaluation.
The effect evaluation methodology: test 0 day shooting experimenter's eyes image as the benchmark data, test was carried out image taking in 2,4,6 and 8 weeks.Adopting photoshop software Lab system to carry out colorimetric analysis calculates, represent eye skin whiteness with L-value, the higher explanation skin of L-value is whiter, with the relative analysis of benchmark data, SPSS statistical result is in order to evaluate product efficacy, and P＜0.1 can be considered to have statistical significance.
Basic components in tester's use table 2 and the compositions in the table 3 are tested.
Table 2 basic components
| Composition | Weight ratio |
| Methyl glucose sesquistearate | 1.2％ |
| Dimethyl siloxane | 1.0％ |
| 16/octadecanol | 3％ |
| Dicaprylyl carbonate | 4％ |
| Sad propyl group heptyl ester | 2％ |
| Soft phospholipid | 2.5％ |
| HANSHENGJIAO | 0.3％ |
| 1,3 butanediol | 4％ |
| EDTA-2Na | 0.2％ |
| Glycerol | 2.0％ |
| Triethanolamine | 2％ |
| Lactic acid | In right amount, adjust pH to 4.0～6.0 |
| Antiseptic | In right amount |
| Water | Add to 100% |
Table 3 compositions
Carry out following paired comparison:
Paired comparison 1: compositions 1 (basic components) is to compositions 2 (basic components+0.5% neohesperidin);
Paired comparison 2: compositions 1 (basic components) is to compositions 3 (basic components+2% neohesperidin);
Paired comparison 3: compositions 1 (basic components) is to compositions 4 (basic components+10% neohesperidin extract).
4A to 4C is shown in the results are shown in of obtaining:
1 pair of black-eyed average improvement of table 4A paired comparison
| Week | Basic components # | Basic components+0.5% neohesperidin |
| 0 | 0 | 0 |
| 2 | 0.8％ | 0.8％ |
| 4 | 1.0％ | 1.2％ |
| 6 | 1.5％ | 2.2％ ＊＊ |
| 8 | 1.2％ | 2.2％ ＊＊ |
*Basic components+0.5% neohesperidin began to provide than remarkable larger the improving of basic components (P＜0.05) in use in 6 weeks.
Changing also appears in the basic components of # non-activity composition, deducts the accuracy that this variation helps to provide test.This basic components occurring causes of change occurs and may include but not limited to: the stimulation of basic components itself, be subjected to the non-objective factors such as caloric stimulation, emotion and shooting environmental shading value.These factors all may cause L-value to change, thereby reduce the objectivity of test result, therefore need strict control experiment condition in experimentation.The right and left eyes own control is set in experimental technique, can farthest eliminate or the balance test process in the impact of irrelevant variable, so difference of experimental group and matched group, can regard as is effect from experimental variable.As in the present embodiment, test result shows that the L-value of smearing basic components one side all has increase in various degree within the different testing times, explanation non-objective factor under this experiment condition has certain impact to L-value, and the degree of smearing the L-value increase of adding neohesperidin one side is higher, compare with the former and to have significance, and illustrate that this significance is due to the effect of neohesperidin.
2 pairs of black-eyed average improvement of table 4B paired comparison
| Week | Basic components | Basic components+2% neohesperidin |
| 0 | 0 | 0 |
| 2 | 1.2％ | 1.5％ |
| 4 | 1.0％ | 2.3％ ＊＊ |
| 6 | 1.5％ | 2.5％ ＊＊ |
| 8 | 1.5％ | 2.9％ ＊＊ |
*Basic components+2% neohesperidin began to provide than remarkable larger the improving of basic components (P＜0.05) in use in 4 weeks.
3 pairs of black-eyed average improvement of table 4C paired comparison
| Week | Basic components | Basic components+10% neohesperidin extract |
| 0 | 0 | 0 |
| 2 | 1.5％ | 2.5％ ＊＊ |
| 4 | 1.8％ | 3.0％ ＊＊ |
| 6 | 2.0％ | 3.2％ ＊＊ |
| 8 | 1.2％ | 3.8％ ＊＊ |
*Basic components+10% neohesperidin extract began to provide than remarkable larger the improving of basic components (P＜0.05) in use in 2 weeks
Above paired comparison result shows, added neohesperidin in the compositions after, compare with the compositions of not adding neohesperidin, have and improve significantly black-eyed effect.This embodiment illustrates that neohesperidin can be used for improving particularly skin microcirculation near the eyes of skin microcirculation, especially as dispelling black-eyed cosmetics skin-protection product.
Above embodiment has illustrated topical compositions of the present invention, and described compositions can be processed in a usual manner.They are suitable for the cosmetic skin care purposes, and described compositions is suitable for dispelling black eye to improve eye part skin the look and feel specifically.
Claims (7)
1. neohesperidin or the plant extract that comprises neohesperidin are for the preparation of improving and/or promote skin microcirculation, perhaps eliminate and/or the product of the bad relevant disease of alleviation and skin microcirculation or state in purposes, neohesperidin content is not less than 50 % by weight in the wherein said plant extract that comprises neohesperidin.
2. according to claim 1 purposes, wherein said skin microcirculation is the eye part skin microcirculation.
3. according to claim 1 and 2 purposes wherein saidly refers to and the bad relevant disease of eye part skin microcirculation or state with the bad relevant disease of skin microcirculation or state.
4. according to claim 3 purposes wherein saidly refers to black eye with the bad relevant disease of eye part skin microcirculation or state.
5. according to claim 1 and 2 purposes, the wherein said plant extract that comprises neohesperidin refers to extract the extract that obtains by the fruit of Rutaceae Poncirus plant trifoliate orange (Poncirus trifoliata (L.) Raf.).
6. according to claim 1 and 2 purposes, wherein said product is the product of local application.
7. according to claim 1 and 2 purposes comprises in the wherein said product: (1) neohesperidin or comprise the plant extract of neohesperidin, and the acceptable excipient of (2) physiology.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010264502 CN102258528B (en) | 2010-08-25 | 2010-08-25 | Application of new hesperidin |
| HK12101207.3A HK1160777A1 (en) | 2010-08-25 | 2012-02-08 | Novel use of neohesperidoside |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010264502 CN102258528B (en) | 2010-08-25 | 2010-08-25 | Application of new hesperidin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102258528A CN102258528A (en) | 2011-11-30 |
| CN102258528B true CN102258528B (en) | 2013-10-23 |
Family
ID=45005494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010264502 Active CN102258528B (en) | 2010-08-25 | 2010-08-25 | Application of new hesperidin |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN102258528B (en) |
| HK (1) | HK1160777A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2783690B1 (en) | 2011-11-25 | 2017-04-26 | Natural Medicine Institute of Zhejiang Yangshengtang Co., Ltd. | New use of neohesperidin |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1836665A (en) * | 2005-03-21 | 2006-09-27 | 江西天科医药开发有限公司 | Pharmaceutical uses of hesperidin or its composition |
-
2010
- 2010-08-25 CN CN 201010264502 patent/CN102258528B/en active Active
-
2012
- 2012-02-08 HK HK12101207.3A patent/HK1160777A1/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1836665A (en) * | 2005-03-21 | 2006-09-27 | 江西天科医药开发有限公司 | Pharmaceutical uses of hesperidin or its composition |
Non-Patent Citations (2)
| Title |
|---|
| 岳学状等.橙皮苷、β-七叶皂苷、丹参酮等局部外用对甲皱皮肤微循环的影响.《临床皮肤杂志》.2005,第34卷(第7期), * |
| 李玉山.橙皮苷研究新进展.《科技导报》.2009,第27卷(第22期),108-115. * |
Also Published As
| Publication number | Publication date |
|---|---|
| HK1160777A1 (en) | 2012-08-17 |
| CN102258528A (en) | 2011-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106176274A (en) | A kind of peptide composition with antiallergic effect | |
| CN110638709A (en) | Anti-blue-light multi-effect repair eye cream and preparation method thereof | |
| CN109731001A (en) | The newly new application of fine jade oligosaccharides and the composition containing new fine jade oligosaccharides | |
| CN101357109A (en) | Chinese daily chemical articles composition | |
| CN102266320B (en) | New application of hesperetin | |
| CN105534796A (en) | Anti-allergic toner containing folium artemisiae argyi extract and preparation method thereof | |
| CN103494719B (en) | Preparation method of anti-aging cream | |
| CN113081874A (en) | Personalized beauty treatment method based on skin | |
| CN104188859B (en) | A kind of crease-resistant skin care emulsion containing natural component extract and preparation method thereof | |
| CN102258528B (en) | Application of new hesperidin | |
| CN108703917B (en) | Anti-aging composition and cosmetic prepared from same | |
| CN116251047B (en) | Oil-control hair-washing agent containing burdock root extract and preparation method thereof | |
| CN105534815B (en) | A kind of skin care compositions and preparation method thereof containing lotus active constituent | |
| CN110179715A (en) | Black eye of dispelling composition, black eye of dispelling eye mask and preparation method thereof | |
| US11260011B2 (en) | Use of neohesperidin | |
| CN104224561A (en) | New application of hesperetin | |
| CN105327342A (en) | Ointment for treating skin eczema and insect bite dermatitis and preparation method of ointment | |
| EP0319058A1 (en) | Hair growth composition | |
| CN106166256B (en) | External medicine composition, preparation with antiallergic itching-relieving efficacies and preparation method thereof | |
| CN108888561A (en) | A kind of lightening compositions and its cosmetics of preparation | |
| TWI421098B (en) | New use of new hesperidin | |
| TWI712416B (en) | Use of extract of sphagneticola trilobata for anti-inflammation of skin and promoting keratinocyte proliferation | |
| TWI491404B (en) | New use of hesperetin | |
| CN110064009A (en) | It is a kind of alleviate asthenopia composition and its application | |
| CN115737460A (en) | Natural moisturizing and antioxidant smearing type mask and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1160777 Country of ref document: HK |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20111130 Assignee: Hainan Yangshengtang Pharmaceutical Co., Ltd. Assignor: Zhejiang Yangshengtang Natrual Medicine Inst. Co., Ltd. Contract record no.: 2014990000174 Denomination of invention: New application of new hesperidin Granted publication date: 20131023 License type: Exclusive License Record date: 20140402 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1160777 Country of ref document: HK |